spacer
home > ebr > autumn 2003 > upping the anti - keeping ahead of antibiotic resistance
PUBLICATIONS
European Biopharmaceutical Review

Upping the Anti - Keeping Ahead of Antibiotic Resistance

The prevalence of antibacterial resistance seems to be rising, yet few new antibiotics have been approved in recent years. How dire is the situation and what is Enanta doing to address it?

Drug resistance is continually increasing and the supply of new antibiotics has slowed. Resistance to antibiotics varies by geographic region and there is no doubt that clinically important species of bacteria such as Streptococci, one of the major causes of respiratory tract infections, have developed resistance to more than one antibiotic. A recent study completed by the Centers for Disease Control in the US concluded that by next year 40 per cent of Streptococci will be resistant to both penicillins and macrolides.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Aimee Dingwell, News Editor at BioCentury Publications Inc, talks to Spiros Jamas, President and CEO of Enanta

Dr Spiros Jamas graduated from the University of Manchester Institute of Science and Technology, England, in 1981 with a BSc (Hons) in Chemical Engineering. He also holds a MSc in Food Science and Technology and a PhD in Biotechnology from the Massachusetts Institute of Technology.

In 1988, Dr Jamas founded and served as President, CEO and Director of Alpha-Beta Technology, a company that developed medical applications of carbohydrates. During his tenure at Alpha-Beta, he was instrumental in raising $200 million through venture capital, as well as public financings. Dr Jamas has also directed two INDs, five Phase I, three Phase II, and two Phase III clinical trials, while concurrently acquiring another privately held biotechnology company. Following this, he held the position of President and CEO of Repair Inc, a biopharmaceutical company that developed sustained-release angiogenesis therapies for the repair of diseased organs and tissues.

Dr Jamas has served as President and CEO of Enanta since the company's inception in 1999, providing scientific and business leadership.

spacer
Aimee Dingwell
spacer
spacer
spacer
Dr Spiros Jamas
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Interview with the Winner of the 1st ever Central Eastern European Pharmaceutical Manufacturing Excellence Award

ABB, together with its customer Gedeon Richter, won the 1st ever CEE Pharmaceutical Manufacturing Excellence Award in the solution provider category at PHARM Connect
More info >>

White Papers

Convergence in the Pharmaceutical Market

Packaging Coordinators, Inc.

Convergence is currently playing a large part in the growth of the pharmaceutical market. The need for convergence is due to many factors including the declining economy and high competition within the sector. There are many convergences within this sector to date; these include the convergence of food based products with medical and health products and the convergence of prescription drugs to over the counter (OTC) products. Although convergence is helping the pharmaceutical industry expand and develop, it also poses some challenges; these include the regulatory outlook and counterfeiting.
More info >>

 
Industry Events

ISPPP 2015, 35th Symposium and Exhibit on the Separation and Characterization of Biologically Important Molecules

29-31 July 2015, Philadelphia, PA, USA

Don't miss cutting-edge presentations delivered by world renowned who will discuss new advances and applications, as well as the challenges and novel approaches for the Separation, Purification, and Characterization of Biologically Important Molecules.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement